about
Resistance of Hepatitis C Virus to Inhibitors: Complexity and Clinical ImplicationsThe phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infectionThe missing pieces of the HCV entry puzzle.Establishment of hepatitis C virus RNA-replicating cell lines possessing ribavirin-resistant phenotype.Association with Spontaneous Hepatitis C Viral Clearance and Genetic Differentiation of IL28B/IFNL4 Haplotypes in Populations from MexicoOnce-daily dose regimen of ribavirin is interchangeable with a twice-daily dose regimen: randomized open clinical trial.Design, synthesis and antiviral evaluation of 2'-C-methyl branched guanosine pronucleotides: the discovery of IDX184, a potent liver-targeted HCV polymerase inhibitor.Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.Immunization With a Subunit Hepatitis C Virus Vaccine Elicits Pan-Genotypic Neutralizing Antibodies and Intrahepatic T-Cell Responses in Nonhuman Primates.Temporal dynamics of hepatitis C genotypes in a five-year hospital-based surveillance in Northern Italy.HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients.Genetic Analysis of Serum-derived HCV Defective Genomes Revealed Novel Viral Cis-Elements for Virus Replication and Assembly.Hepatitis C virus NS5A protein promotes the lysosomal degradation of hepatocyte nuclear factor 1α via chaperone-mediated autophagy.
P2860
Q26777408-D37BE501-CB0C-4062-A490-B634422AAB86Q30252649-19ED61EA-5A0F-477C-98A9-2CC809307531Q33360674-8E7F2D76-2E42-4D5A-AF48-B52C80F9F5ABQ35564506-D842E6A5-5B21-4B5C-82CD-337CCD1AE79EQ35887966-C90A0181-FAB9-4607-9F78-BBFC4C2BDE59Q36120739-797E136C-CDF6-4E75-A166-E46FE8F7A4AAQ38958064-7142B0B6-8487-43DB-BA9B-78F0133CD0FEQ39104215-0FD378B8-C1F5-4F63-9544-72E89EE1169AQ40248234-DC6FADA4-0590-4EF9-BEB5-12E9A6B002D2Q40611739-F292CA40-AEDA-436E-AF01-BD32AF74C8F3Q47138788-FB24878B-92E8-47D5-9C8B-FB222FD62305Q47549190-86A1F941-5A08-4EBC-BCC4-D69997C9FB10Q52716681-F0D4D445-D36E-4721-85FB-645BB27CF094
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Emerging treatments for chronic hepatitis C.
@en
type
label
Emerging treatments for chronic hepatitis C.
@en
prefLabel
Emerging treatments for chronic hepatitis C.
@en
P1476
Emerging treatments for chronic hepatitis C.
@en
P2093
C Nelson Hayes
Kazuaki Chayama
P304
P356
10.1016/J.JFMA.2014.09.001
P577
2014-10-07T00:00:00Z